This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The timely update by Dr Stern and colleagues¹ on emerging issues in early detection of prostate and colorectal cancers raised many important points, some of which require clarification and emphasis.

The American Cancer Society (ACS) recognizes that there exist differing opinions as to whether early detection testing for prostate cancer lowers disease-specific mortality. Our updated guidelines of June 1997 advise physicians and other clinicians to offer early-detection testing for prostate cancer to appropriate patients and to provide information to patients on the test's potential risks and benefits.² The casual reader of the article by Stern et al might erroneously construe that ACS supports "mass" screening.

Studies have shown that, when men are provided with more formal information regarding early-detection testing for prostate cancer, many decline it.³ The ACS is concerned that men may be undergoing screening without proper pretest guidance and education and agree that routine serum . . . [Full Text of this Article]

RELATED ARTICLE

Are -Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review
Franz H. Messerli, Ehud Grossman, and Uri Goldbourt
JAMA. 1998;279(23):1903-1907.
ABSTRACT | FULL TEXT